Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A Southwest Oncology Group Study

D. D. Von Hoff, T. R. Fleming, J. S. Macdonald, P. J. Goodman, J. Van Damme, T. D. Brown, T. O'Rourke, Lynn G Feun, M. D. Keppen

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Thirty evaluable patients with advanced carcinoma of the pancreas received treatment with either daily x 5 bolus or continuous infusion x 5 days recombinant γ-interferon. No responses were noted. Major toxicities included fever, hypotension, and flu-like symptoms. γ-Interferon does not appear to be an active single agent for patients with advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)584-587
Number of pages4
JournalJournal of Biological Response Modifiers
Volume9
Issue number6
StatePublished - Dec 1 1990

    Fingerprint

Keywords

  • γ-Interferon
  • Pancreatic cancer

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Von Hoff, D. D., Fleming, T. R., Macdonald, J. S., Goodman, P. J., Van Damme, J., Brown, T. D., O'Rourke, T., Feun, L. G., & Keppen, M. D. (1990). Phase II evaluation of recombinant γ-interferon in patients with advanced pancreatic carcinoma: A Southwest Oncology Group Study. Journal of Biological Response Modifiers, 9(6), 584-587.